MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, RNTX had -$1,674K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$1,674K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-5,581 -12,323
Commitment fee related to pre-paid advance agreement
300 -
Original issue discount related to pre-paid advance agreement
100 -
Depreciation and amortization expense
0 1
Stock-based compensation expense
1,447 520
Prepaid expenses and other current assets
219 115
Other assets
-2,344 2,344
Accounts payable
-1,905 5,117
Operating lease liabilities
0 0
Accrued expenses and other current liabilities
-34 -3,172
Other long-term liabilities
0 -277
Net cash used in operating activities
-3,548 -12,593
Proceeds from issuance of common stock, net of offering costs
0 367
Proceeds from pre-paid advances
1,900 -
Proceeds from issuance of common stock in connection with stock option exercises
0 1
Proceeds from issuance of common stock in connection with warrant exercises
0 1,595
Proceeds from issuance of warrants, net of offering costs
0 481
Proceeds from warrant exchanges, net of offering costs
0 2,984
Proceeds from warrant exercises with common stock subscribed
0 22
Net cash provided by financing activities
1,900 5,450
Effect of exchange rate changes on cash and cash equivalents
-26 0
Net (decrease) increase in cash, cash equivalents and restricted cash
-1,674 -7,143
Cash and cash equivalents at beginning of period
12,865 -
Cash and cash equivalents at end of period
4,048 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Rein Therapeutics, Inc. (RNTX)

Rein Therapeutics, Inc. (RNTX)